Expression of Estrogen Receptor-α and Survival in Advanced-stage Non-small Cell Lung Cancer.

Anticancer Res 2018 04;38(4):2261-2269

Department of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, Norway.

Background/aim: The favorable prognosis of women with non-small-cell lung cancer (NSCLC) compared to men might be explained by sex hormone-related mechanisms. We investigated whether this observation could be explained by the expression of estrogen receptor-alpha (ER-α) in tumor tissue.

Materials And Methods: Archived, formalin fixed, paraffin embedded tumor tissue samples were retrospectively analyzed for nuclear expression of ER-α with immunohistochemistry.

Results: Biopsies from 222 patients were analyzed. Twenty-three percent were ER-α positive. Fifty-four percent of the patients were men and 46% of the tumors were adenocarcinomas. One hundred-nine (49%) patients received pemetrexed and carboplatin and 113 (51%) received gemcitabine and carboplatin. Females with ER-α positive tumors who received PC had a substantial survival benefit over all other groups (20 vs. 4.6 months; p=0.003).

Conclusion: ER-α is an independent prognostic factor in advanced NSCLC and might also be a predictive factor for response to pemetrexed/carboplatin in women.

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.12470DOI Listing
April 2018
10 Reads

Publication Analysis

Top Keywords

er-α positive
8
lung cancer
8
expression estrogen
8
er-α
5
positive fifty-four
4
percent er-α
4
analyzed twenty-three
4
twenty-three percent
4
fifty-four percent
4
percent patients
4
adenocarcinomas hundred-nine
4
hundred-nine 49%
4
tumors adenocarcinomas
4
46% tumors
4
patients men
4
men 46%
4
patients analyzed
4
222 patients
4
tissue samples
4
samples retrospectively
4

Similar Publications